Thrasos Innovation Inc. kicked off a Phase I trial investigating the safety and tolerability of THR-184, an activator of specific receptors in the bone morphogenetic protein (BMP) receptor pathway. The peptides are designed to help protect and repair acutely injured kidneys. Although acute kidney injury (AKI) is a source of significant morbidity and mortality following surgery – and a major frustration for physicians – there is no approved drug therapy for the condition.